Bipolar Depression Pipeline Analysis, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical/Non-Clinical Trial Activities, Emerging Therapies, and Key Companies by DelveInsight

As per DelveInsight, the Bipolar Depression therapeutics market is expected to evolve significantly in the coming years owing to growth in the novel insights into the disease, improvement in treatment scenarios, future growth in blood biomarkers, increase in awareness and technological advances towards precision medicine for Bipolar Depression.

"Bipolar Depression Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Bipolar Depression Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Bipolar Depression Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Bipolar Depression Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bipolar Depression treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Bipolar Depression market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Bipolar Depression Therapeutics Analysis
In Bipolar Depression, a greater prevalence of atypical features or reverse neurovegetative symptoms, such as hypersomnia or hyperphagia, was reported by most studies but not all. A past depressive episode plus at least one episode of mania or hypomania are signs that one has Bipolar Depression.

At present, there are only 3 approved drug treatments for Acute Bipolar Depression, which include, olanzapine/fluoxetine combination, quetiapine (immediate or extended-release), and lurasidone (monotherapy or adjunctive to lithium or valproate). To further improve the treatment scenario, globally, several key companies are actively working in the Bipolar Depression therapeutics market. The ultimate goal of treatment is to achieve a high level of psychosocial function and health-related quality of life.

As per DelveInsight's assessment, there are approx. 6+ key companies which are developing therapies for Bipolar Depression. Currently, Intra-Cellular Therapies has its Bipolar Depression drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Bipolar Depression Therapeutics Market Include
- Intra-Cellular Therapies
- unovion Pharmaceuticals
- COMPASS Pathways
- Lundbeck
- SAGE Therapeutics
- NRx Pharmaceuticals
- Clexio Biosciences
- Iltoo Pharma
And many others

Bipolar Depression Emerging Drugs Covered In the Report Include
- Lumateperone: Intra-Cellular Therapies
- Zuranolone: SAGE Therapeutics
- CLE-100: Clexio Biosciences
- SEP-4199: Sumitomo Dainippon Pharma
- NRX100: NeuroRx, Inc.
- NRX101: NeuroRx, Inc.
- ILT101: Iltoo Pharma
And Many More

Bipolar Depression Therapeutics Assessment by Mechanism of Action (MoA)
- GABA A receptor modulators
- Dopamine D2 receptor antagonists
- Interleukin-2 replacements
- NMDA receptor modulators
- Serotonin receptor modulators

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Bipolar Depression Current Treatment Patterns
4. Bipolar Depression - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Bipolar Depression Late Stage Products (Phase-III)
7. Bipolar Depression Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Bipolar Depression Discontinued Products
13. Bipolar Depression Product Profiles
14. Bipolar Depression Key Companies
15. Bipolar Depression Key Products
16. Dormant and Discontinued Products
17. Bipolar Depression Unmet Needs
18. Bipolar Depression Future Perspectives
19. Bipolar Depression Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.